OCS
Oculis Holding AG
NASDAQ · Healthcare · Biotechnology · CH
$7.28
−4.59%Next report
Analyst consensus
- Next report date
- Mar 22, 2027
- EPS estimate
- -$0.51
- Revenue estimate
- $299.9K
Latest reported
- Last report date
- Nov 3, 2026
- EPS actual
- -$0.37
- EPS estimate
- -$0.47
- Revenue actual
- —
- Revenue estimate
- $260.2K
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 3
- EPS misses (12Q)
- 8
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- +8.2%
- Revenue beats (12Q)
- 6
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $33
- PT range
- $20 – $40
- Analysts
- 3
3 Buy0 Hold0 Sell
No earnings call summaries available
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Nov 3, 2026 | -$0.47 | -$0.37 | Beat 21.49% | $8.1K |
| Aug 6, 2026 | -$0.48 | -$0.20 | Beat 58.33% | $371.1K |
| May 11, 2026 | -$0.49 | -$0.63 | Miss -28.57% | $253.2K |
| Mar 3, 2026 | -$0.43 | -$0.51 | Miss -18.60% | $518.4K |
| Aug 21, 2025 | -$0.53 | -$0.59 | Miss -11.32% | $328.5K |
| May 8, 2025 | -$0.51 | -$0.77 | Miss -50.98% | $321.9K |
| Mar 11, 2025 | -$0.48 | -$0.76 | Miss -58.33% | $3.3K |
| Nov 7, 2024 | -$0.52 | -$0.55 | Miss -5.77% | $236.0K |
| Mar 18, 2024 | -$0.42 | -$0.38 | Beat 9.52% | $216.2K |
| Nov 15, 2023 | -$0.36 | -$0.38 | Miss -5.56% | $238.8K |
| Aug 29, 2023 | -$0.33 | -$0.38 | Miss -15.15% | $278.7K |
| Mar 31, 2023 | — | -$1.51 | — | $261.4K |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Mar 22, 2027